These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20121563)

  • 1. Explanatory versus pragmatic trial-based economic evaluations: application to alternative therapies for burns.
    Carayanni V; Tsati E
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):37-48. PubMed ID: 20121563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pragmatic vs. explanatory: an adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice.
    Koppenaal T; Linmans J; Knottnerus JA; Spigt M
    J Clin Epidemiol; 2011 Oct; 64(10):1095-101. PubMed ID: 21474282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pragmatic clinical trials.
    Macpherson H
    Complement Ther Med; 2004; 12(2-3):136-40. PubMed ID: 15561524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
    Thorpe KE; Zwarenstein M; Oxman AD; Treweek S; Furberg CD; Altman DG; Tunis S; Bergel E; Harvey I; Magid DJ; Chalkidou K
    J Clin Epidemiol; 2009 May; 62(5):464-75. PubMed ID: 19348971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new 'mechanistic-practical" framework for designing and interpreting randomized trials.
    Karanicolas PJ; Montori VM; Devereaux PJ; Schünemann H; Guyatt GH
    J Clin Epidemiol; 2009 May; 62(5):479-84. PubMed ID: 18468856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity.
    Godwin M; Ruhland L; Casson I; MacDonald S; Delva D; Birtwhistle R; Lam M; Seguin R
    BMC Med Res Methodol; 2003 Dec; 3():28. PubMed ID: 14690550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Explanatory versus pragmatic trials? The methods make the difference.
    Merckx P; Paugam-Burtz C; Boudinet S; Bonnet A; Mantz J
    Anesthesiology; 2008 Mar; 108(3):542-3; author reply 543-4. PubMed ID: 18292699
    [No Abstract]   [Full Text] [Related]  

  • 9. Study control, violators, inclusion criteria and defining explanatory and pragmatic trials.
    McMahon AD
    Stat Med; 2002 May; 21(10):1365-76. PubMed ID: 12185890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new measure. New studies require new criteria for critical appraisal].
    Donner-Banzhoff N; Lelgemann M
    Z Arztl Fortbild Qualitatssich; 2003 Jul; 97(4-5):301-6. PubMed ID: 12891974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do randomized controlled nursing trials have a pragmatic or explanatory attitude? Findings from the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool exercise.
    Palese A; Bevilacqua MG; Dante A;
    J Nurs Res; 2014 Sep; 22(3):216-20. PubMed ID: 25111115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical considerations in the design of clinical trials.
    Carter SK
    Cancer Treat Rep; 1980; 64(2-3):367-71. PubMed ID: 7407773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Roaming through methodology. XII. Pragmatic and pathophysiologic trials: a question of goal formulation].
    Algra A; van der Graaf Y
    Ned Tijdschr Geneeskd; 1999 Mar; 143(10):514-7. PubMed ID: 10321260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.